Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil

Otavio T. Ranzani; Matt D.T. Hitchings; Rosana Leite de Melo; Giovanny V.A. de França; Cássia de Fátima R. Fernandes; Margaret L. Lind; Mario Sergio Scaramuzzini Torres; Daniel Henrique Tsuha; Leticia C.S. David; Rodrigo F.C. Said; Maria Almiron; Roberto D. de Oliveira; Derek A.T. Cummings; Natalie E. Dean; Jason R. Andrews; Albert I. Ko; Julio Croda

doi:10.1038/s41467-022-33169-0

Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil

Otavio T. Ranzani
, Matt D.T. Hitchings
, Rosana Leite de Melo
, Giovanny V.A. de França
, Cássia de Fátima R. Fernandes
, Margaret L. Lind
, Mario Sergio Scaramuzzini Torres
, Daniel Henrique Tsuha
, Leticia C.S. David
, Rodrigo F.C. Said
, Maria Almiron
, Roberto D. de Oliveira
, Derek A.T. Cummings
, Natalie E. Dean
, Jason R. Andrews
, Albert I. Ko
, Julio Croda

Research output: Contribution to journal › Article › peer-review

Abstract

The effectiveness of inactivated vaccines (VE) against symptomatic and severe COVID-19 caused by omicron is unknown. We conducted a nationwide, test-negative, case-control study to estimate VE for homologous and heterologous (BNT162b2) booster doses in adults who received two doses of CoronaVac in Brazil in the Omicron context. Analyzing 1,386,544 matched-pairs, VE against symptomatic disease was 8.6% (95% CI, 5.6–11.5) and 56.8% (95% CI, 56.3–57.3) in the period 8–59 days after receiving a homologous and heterologous booster, respectively. During the same interval, VE against severe Covid-19 was 73.6% (95% CI, 63.9–80.7) and 86.0% (95% CI, 84.5–87.4) after receiving a homologous and heterologous booster, respectively. Waning against severe Covid-19 after 120 days was only observed after a homologous booster. Heterologous booster might be preferable to individuals with completed primary series inactivated vaccine.

Original language	English (US)
Article number	5536
Journal	Nature communications
Volume	13
Issue number	1
DOIs	https://doi.org/10.1038/s41467-022-33169-0
State	Published - Dec 2022
Externally published	Yes

ASJC Scopus subject areas

General Chemistry
General Biochemistry, Genetics and Molecular Biology
General
General Physics and Astronomy

Access to Document

10.1038/s41467-022-33169-0

Cite this

Ranzani, O. T., Hitchings, M. D. T., de Melo, R. L., de França, G. V. A., Fernandes, C. D. F. R., Lind, M. L., Torres, M. S. S., Tsuha, D. H., David, L. C. S., Said, R. F. C., Almiron, M., de Oliveira, R. D., Cummings, D. A. T., Dean, N. E., Andrews, J. R., Ko, A. I., & Croda, J. (2022). Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil. Nature communications, 13(1), Article 5536. https://doi.org/10.1038/s41467-022-33169-0

Ranzani, OT, Hitchings, MDT, de Melo, RL, de França, GVA, Fernandes, CDFR, Lind, ML, Torres, MSS, Tsuha, DH, David, LCS, Said, RFC, Almiron, M, de Oliveira, RD, Cummings, DAT, Dean, NE, Andrews, JR, Ko, AI & Croda, J 2022, 'Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil', Nature communications, vol. 13, no. 1, 5536. https://doi.org/10.1038/s41467-022-33169-0

@article{1e1d9b6a67354bd4bc20366fc882ea32,

title = "Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil",

abstract = "The effectiveness of inactivated vaccines (VE) against symptomatic and severe COVID-19 caused by omicron is unknown. We conducted a nationwide, test-negative, case-control study to estimate VE for homologous and heterologous (BNT162b2) booster doses in adults who received two doses of CoronaVac in Brazil in the Omicron context. Analyzing 1,386,544 matched-pairs, VE against symptomatic disease was 8.6\% (95\% CI, 5.6–11.5) and 56.8\% (95\% CI, 56.3–57.3) in the period 8–59 days after receiving a homologous and heterologous booster, respectively. During the same interval, VE against severe Covid-19 was 73.6\% (95\% CI, 63.9–80.7) and 86.0\% (95\% CI, 84.5–87.4) after receiving a homologous and heterologous booster, respectively. Waning against severe Covid-19 after 120 days was only observed after a homologous booster. Heterologous booster might be preferable to individuals with completed primary series inactivated vaccine.",

author = "Ranzani, \{Otavio T.\} and Hitchings, \{Matt D.T.\} and \{de Melo\}, \{Rosana Leite\} and \{de Fran{\c c}a\}, \{Giovanny V.A.\} and Fernandes, \{C{\'a}ssia de F{\'a}tima R.\} and Lind, \{Margaret L.\} and Torres, \{Mario Sergio Scaramuzzini\} and Tsuha, \{Daniel Henrique\} and David, \{Leticia C.S.\} and Said, \{Rodrigo F.C.\} and Maria Almiron and \{de Oliveira\}, \{Roberto D.\} and Cummings, \{Derek A.T.\} and Dean, \{Natalie E.\} and Andrews, \{Jason R.\} and Ko, \{Albert I.\} and Julio Croda",

note = "Publisher Copyright: {\textcopyright} 2022, The Author(s).",

year = "2022",

month = dec,

doi = "10.1038/s41467-022-33169-0",

language = "English (US)",

volume = "13",

journal = "Nature communications",

issn = "2041-1723",

publisher = "Nature Research",

number = "1",

}

TY - JOUR

T1 - Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil

AU - Ranzani, Otavio T.

AU - Hitchings, Matt D.T.

AU - de Melo, Rosana Leite

AU - de França, Giovanny V.A.

AU - Fernandes, Cássia de Fátima R.

AU - Lind, Margaret L.

AU - Torres, Mario Sergio Scaramuzzini

AU - Tsuha, Daniel Henrique

AU - David, Leticia C.S.

AU - Said, Rodrigo F.C.

AU - Almiron, Maria

AU - de Oliveira, Roberto D.

AU - Cummings, Derek A.T.

AU - Dean, Natalie E.

AU - Andrews, Jason R.

AU - Ko, Albert I.

AU - Croda, Julio

PY - 2022/12

Y1 - 2022/12

N2 - The effectiveness of inactivated vaccines (VE) against symptomatic and severe COVID-19 caused by omicron is unknown. We conducted a nationwide, test-negative, case-control study to estimate VE for homologous and heterologous (BNT162b2) booster doses in adults who received two doses of CoronaVac in Brazil in the Omicron context. Analyzing 1,386,544 matched-pairs, VE against symptomatic disease was 8.6% (95% CI, 5.6–11.5) and 56.8% (95% CI, 56.3–57.3) in the period 8–59 days after receiving a homologous and heterologous booster, respectively. During the same interval, VE against severe Covid-19 was 73.6% (95% CI, 63.9–80.7) and 86.0% (95% CI, 84.5–87.4) after receiving a homologous and heterologous booster, respectively. Waning against severe Covid-19 after 120 days was only observed after a homologous booster. Heterologous booster might be preferable to individuals with completed primary series inactivated vaccine.

AB - The effectiveness of inactivated vaccines (VE) against symptomatic and severe COVID-19 caused by omicron is unknown. We conducted a nationwide, test-negative, case-control study to estimate VE for homologous and heterologous (BNT162b2) booster doses in adults who received two doses of CoronaVac in Brazil in the Omicron context. Analyzing 1,386,544 matched-pairs, VE against symptomatic disease was 8.6% (95% CI, 5.6–11.5) and 56.8% (95% CI, 56.3–57.3) in the period 8–59 days after receiving a homologous and heterologous booster, respectively. During the same interval, VE against severe Covid-19 was 73.6% (95% CI, 63.9–80.7) and 86.0% (95% CI, 84.5–87.4) after receiving a homologous and heterologous booster, respectively. Waning against severe Covid-19 after 120 days was only observed after a homologous booster. Heterologous booster might be preferable to individuals with completed primary series inactivated vaccine.

UR - https://www.scopus.com/pages/publications/85139330546

UR - https://www.scopus.com/pages/publications/85139330546#tab=citedBy

U2 - 10.1038/s41467-022-33169-0

DO - 10.1038/s41467-022-33169-0

M3 - Article

C2 - 36202800

AN - SCOPUS:85139330546

SN - 2041-1723

VL - 13

JO - Nature communications

JF - Nature communications

IS - 1

M1 - 5536

ER -

Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this